Daiwa Securities Group Inc. Sab Biotherapeutics, Inc. Transaction History

Daiwa Securities Group Inc.

  • $21.6 Billion
  • Q3 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 03, 2022
BUY
$7.3 - $11.24 $927 - $1,427
127 New
127 $1,000

Others Institutions Holding SABS

# of Institutions
3
Shares Held
529K
Call Options Held
0
Put Options Held
0
View Full List

About SAB Biotherapeutics, Inc.

SABS Quotes by TradingView
  • Ticker SABS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,030,900
  • Market Cap $133M
  • Description
  • SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases ...
More about SABS
Track This Portfolio

Track Daiwa Securities Group Inc. Portfolio

Follow Daiwa Securities Group Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Daiwa Securities Group Inc., based on Form 13F filings with the SEC.

News

Stay updated on Daiwa Securities Group Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email